This article is part of the supplement: Basic science, rationale, background and future of denosumab: a RANK ligand inhibitor

Highly Accessed

Review

Clinical development of anti-RANKL therapy

Edward M Schwarz^* and Christopher T Ritchlin

* Corresponding author: Edward M Schwarz edward_schwarz@urmc.rochester.edu

Arthritis Research & Therapy 2007, 9(Suppl 1):S7 doi:10.1186/ar2171

No comments have yet been made on this article.